
Danish pharmaceutical giant Novo Nordisk is saying goodbye to its chief executive amid growing competition for its blockbuster weight loss drugs Wegovy and Ozempic.
Lars Fruergaard Jørgensen, who led the company for eight years, will step down due to “market challenges” and a drop in the company’s share price over the past year, Novo Nordisk said on Friday.